Roca Therapeutics

Roca Therapeutics, based in Nice, France, is a venture capital-financed biotechnology startup focused on developing first-in-class small molecules. As a spin-off from Nice University and SATT Sud Est, and incubated by the PACA Est incubator, the company leverages its internationally recognized team of directors and advisors with a strong track record in translational research and drug development. Roca Therapeutics primarily targets oncology, ophthalmology, and immunology, while also exploring other neoplastic and neovascular disorders as secondary indications. The company has been acknowledged with several prestigious awards, including the i Lab, bpifrance BFTE, PIA3, and the Amgen Prize. Roca's business model involves securing funding through venture capital and non-dilutive financing, having completed a seed funding round in October 2022. The company serves the pharmaceutical and healthcare markets, aiming to provide groundbreaking therapeutic solutions. Keywords: biotechnology, small molecules, oncology, ophthalmology, immunology, venture capital, drug development, translational research, neoplastic disorders, neovascular disorders.